Company Filing History:
Years Active: 2005
Title: The Innovative Contributions of Carmen Elena Gomez Rodriquez
Introduction
Carmen Elena Gomez Rodriquez, a prominent inventor based in Habana, Cuba, has made significant contributions to the field of biotechnology. With a focus on genetic engineering and immunology, she has developed an important patent that reflects her dedication to advancing medical science and vaccine development.
Latest Patents
Carmen's noteworthy patent is titled "Monoclonal antibody to the stabilizer peptide of the P64K antigen of Neisseria meningitidis." This invention pertains to the expression of viral proteins in microorganisms through recombinant DNA technology. Specifically, it outlines a process for producing heterologous proteins as fusion peptides. By employing a stabilizing sequence derived from the first 47 amino acids of the P64K antigen, her innovative approach aims to yield proteins in high purity, which are vital for vaccine formulations. Her patent stands as a testament to her expertise in leveraging biotechnology for public health.
Career Highlights
Carmen currently works at the Centro de Ingeniería Genética y Biotecnología, where she applies her knowledge and skills to enhance research and development initiatives. Her career is marked by a commitment to scientific excellence and a passion for creating solutions that address critical health challenges.
Collaborations
In her innovative journey, Carmen has collaborated with fellow researchers Carlos Antonio Durate Cano and Enrique Gerardo Guillen Nieto. These partnerships reflect her ability to work effectively within teams, fostering an environment of shared knowledge and collective problem-solving, which is essential in the rapidly evolving field of biotechnology.
Conclusion
Carmen Elena Gomez Rodriquez represents a pioneering force in the biotech industry. Her innovative patent and collaborative spirit exemplify the progress being made in the fight against infectious diseases. As she continues her work, Carmen's contributions are likely to have lasting impacts on vaccine development and public health.